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Sununary The expression of mdrl gene product P-glycoprotein (P-gp) was investigated in 53 normal and
reactive bone marrows by means of immunocytochemistry, using the monoclonal antibody (mAb) C219 and the
alkaline phosphatase anti-alkaline phosphatase method. In a limited number of patients, data were confirmed
by using the mAb MRK16 or a polymerase chain reaction assay for mdrl gene expression. There was no
history of prior chemotherapy or any malignancy in this group. Bone marrow aspirates were obtained as part
of a routine diagnostic programme in bone marrow donors or in patients presenting with a variety of
diagnoses such as unexplained gammopathy, fever, anaemia, other changes in peripheral blood smear,
rheumatoid arthritis, vasculitis, or urticaria pigmentosa. Morphologically the bone marrow was normal in 23
patients, a megaloblastic erythropoiesis was seen in two patients and unspecific changes were seen in 28
patients. Twenty-seven of 53 samples were found to be positive for P-gp expression with the percentage of
positive cells ranging from 2%-80% (mean = 24%). With a cutoff point of 10%, five of 23 normal (22%) and
13 of 28 reactive bone marrows (46%) were considered positive for P-gp expression. There was no obvious
correlation between diagnosis or age and P-gp expression. Additional staining for the early surface marker
CD-34 was performed in 12 samples, with none of them revealing more than 1% positivity. Since P-gp
expression has so far been described only in CD-34 positive bone marrow cells, data suggest that P-gp
expression may be reinduced in CD-34 negative cells under conditions which remain to be determined.
The phenomenon of multidrug resistance (mdr) is manifested
by cross resistance to a number of structurally and func-
tionally unrelated lipophilic drugs and has been functionally
associated with the expression of a plasma membrane energy
dependent efflux pump with broad substrate specificity,
termed P-glycoprotein (P-gp), which is the product of the
mdrl gene. Overexpression of the mdrl gene is associated
with decreased sensitivity of tumour cells to natural product
drugs such as anthracyclines, Vinca alkaloids and
epipodophyllotoxins, due to increased energy-dependent drug
efflux. The mdr-phenotype has been frequently observed in a
number of human tumours (Noonan et al., 1990; Schneider
et al., 1989; Chan et al., 1990; Bak et al., 1990) and
haematologic malignancies (Dalton et al., 1989; Pirker et al.,
1989; Holmes et al., 1989; Holmes et al., 1990), both un-
treated and treated with chemotherapeutic drugs and may be
a major reason for the failure of cancer chemotherapy. On
the other hand overexpression of the P-gp has been found in
a variety of normal human tissues, including the liver,
jejunum, colon, kidney, the adrenal cortex, the secretory
epithelium of the uterus and endothelial cells in the brain
(Thiebaut et al., 1987; Arceci et al., 1990; Sugawara et al.,
1988; Cordon-Cardo et al., 1989). The function and regula-
tion of the P-gp in these organs is not yet fully understood
but it may include excretion of toxic substances as well as
other normal metabolites thus serving the body as a major
and general route of detoxification. Although mdrl gene
expression in normal bone marrow cells has been described
to be low or negative (Dalton et al., 1989; Noonan et al.,
1990; Fojo et al., 1987), the mdrl gene expression in de novo
nonlymphoblastic acute leukaemia at diagnosis seems to be a
frequent event. Depending on the method of detection, 46%
to 71% of leukaemia samples are found to be positive for
mdrl expression (Kuwazuru et al., 1990; Pirker et al., 1991;
Campos et al., 1992). Furthermore, there seemed to be a
good correlation between the detection of the mdr-phenotype
and clinical outcome. To deepen the knowledge of the exact
nature of the high incidence of the mdr-phenotype in de novo
acute leukaemia, it therefore seemed interesting to check for
mdrl gene expression in other than leukaemic bone marrows.
Since CD-34 antigen positive hematopoetic stem cells
(Chaudhary & Roninson, 1991) as well as total nucleated
peripheral blood cells and peripheral blood lymphocytes
(Holmes et al., 1990; Neyfakh et al., 1989) were recently
reported to express the mdrl gene it seemed likely to find the
mdr-phenotype not only in haematologic malignancies but
also in bone marrows without malignant infiltrative
disorders. To prove this hypothesis we looked for P-gp ex-
pression in normal bone marrows as well as in reactive
marrows with unspecific changes using the monoclonal
antibodies C219 and MRK16 and immunocytochemistry. To
confirm the results, we have analysed mdrl mRNA expres-
sion by polymerase chain reaction (PCR) amplification in a
limited number of patients. A selected number of patients
was also tested for CD-34 antigen expression using the
monoclonal antibody 8G12. There was no history of prior
chemotherapy or any malignancy in the group of 53 patients
tested.
Material and methods
Patients
Bone marrow aspirates were performed after informed con-
sent as part of a routine diagnostic programme in 53 patients
who came to our outpatient department for various reasons
(see Table I for details) such as planned bone marrow dona-
tion (9), gammopathy of undetermined origin (8), fever (2) or
anaemia (6), leukopenia (2) or leukocytosis (1), thrombo-
cytopenia (3) or thrombocytosis (1), polycythemia (2), recur-
rent viral infections (1), vasculitis (4) or suspected vasculitis
(3), suspected haemoblastosis (1), suspected mycosis fun-
goides (2), osteolytic lesions of undetermined origin (1),
rheumatoid arthritis (2), acne conglobata (1), suspected
Paget's disease (1) or urticaria pigmentosa (3).
The group consisted of 26 men and 27 women. The ages
ranged from 15 to 87 with a mean age of 48 years.
Patient cells
Bone marrow smears were prepared from each patient. After
being air dried they were stained with May-Grunwald-
Giemsa. For immunocytochemical staining cell suspensions
of bone marrow cells enriched by Ficoll-Hypaque density
gradient centrifugation were either used right away or were
cryopreserved in liquid nitrogen until studied.
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Table I Indications for bone marrow (BM) examination, BM-findings and percentage ofcellsexpressing P-glycoprotein, detected by monoclonal
antibodies C219 and MRK16 and immunocytochemistry.
Percentage ofP-glyco-
Patient Indicationfor BM- protein positive cells
no. Sex/Age examination BM-Findings C219 MRK16
BM-donor
BM-donor
BM-donor
BM-donor
BM-donor
BM-donor
BM-donor
BM-donor
BM-donor
Gammopathy of undetermined origin
Gammopathy of undetermined origin
Gammopathy of undetermined origin
Gammopathy of undetermined origin
Gammopathy of undetermined origin
Gammopathy of undetermined origin
Gammopathy of undetermined origin
Gammopathy of undetermined origin
Anaemia
Anaemia
Anaemia
Anaemia
Anaemia
Anaemia
Polycythemia
Polycythemia
Leukopenia
Leukopenia
Leukocytosis
Thrombocytopenia
Thrombocytopenia
Thrombocytopenia, liver cirrhosis
Thrombocytosis post infection
Fever of undetermined origin
Fever of undetermined origin
Recurrent viral infections
Suspected hemoblastosis
Suspected mycosis fungoides
Suspected mycosis fungoides
Osteolytic lesion of undetermined origin
Suspected vasculitis
Suspected vasculitis
Suspected vasculitis
Panarteriitis, Vaskulitis
Vasculitis
Vasculitis
Vasculitis
Rheumatoid arthritis
Rheumatoid arthritis
Acne conglobata
Suspected Paget's disease
Urticaria pigmentosa
Urticaria pigmentosa
Urticaria pigmentosa
Normal marrow
Normal marrow
Reactive marrow
Normal marrow
Normal marrow
Normal marrow
Normal marrow
Normal marrow, iron deficiency
Normal marrow
Normal marrow
Normal marrow
Normal marrow
Normal marrow, increase in plasma cells
Normal marrow
Reactive marrow
Normal marrow
Normal marrow
Normal marrow, iron deficiency
Normal marrow, iron deficiency
Megaloblastic erythropoiesis
Reactive marrow, iron deficiency
Reactive marrow, iron deficiency
Megaloblastic erythropoiesis
Reactive marrow, increase in erythropoesis
Reactive marrow
Normal marrow, iron deficiency
Normal marrow
Reactive marrow
Normal marrow
Reactive marrow, increase in megacaryocytes
Reactive marrow
Reactive marrow
Reactive marrow
Reactive marrow
Normal marrow
Normal marrow
Reactive marrow
Reactive marrow
Reactive marrow
Reactive marrow, iron deficiency
Reactive marrow
Reactive marrow
Reactive marrow
Reactive marrow
Reactive marrow, iron deficiency
Reactive marrow
Normal marrow, iron deficiency
Reactive marrow
Reactive marrow
Reactive marrow
Reactive marrow, mastocytosis
Reactive marrow
Reactive marrow, mastocytosis, iron deficiency
Cell lines
The human lymphoid cell line CEM and the vinblastine
resistant subline CEM/VBL100, which grows in the presence
of 100 ng ml1 vinblastine and shows 270 fold resistance to
vinblastine (Kartner et al., 1983), served as negative or
positive control for antibody staining. Cells were maintained
at a density of 2-5 x 105 cells ml-' in RPMI-1640 media,
supplemented with 5% penicillin-streptomycin, 5% of 200
mM L-glutamine, 10% foetal calf serum and, for CEM/
VBL100, with 100 ng ml-' vinblastine.
Monoclonal antibodies to P-glycoprotein 170
Two monoclonal antibodies known to recognise P-gp were
used. C219 (Centocor, Malvern, Pennsylvania) identifies a
cytoplasmic component of the P-gp (Kartner et al., 1985),
whereas MRK16 (kindly provided by T. Tsuruo) is directed
at an external cellular P-gp 170 epitope (Hamada & Tsuruo,
1986). Both monoclonals are of subclass IgG2a.
Immunocytochemistry
After cytospinning on clean glass slides, cells were air dried
and fixed in ice-cold acetone for 10 min. Each slide was
preincubated for Omin at room temperature in 1% normal
rabbit serum/1% bovine serum albumin (BSA)/tris buffered
saline (TBS, pH 7.6). C219 and MRK16 were diluted in TBS
plus 1% BSA at a final concentration of 10pgml- . The
slides were incubated with the primary antibodies for 2 h at
37TC and rinsed briefly in TBS. The cells were then exposed
to a rabbit anti-mouse immunoglobulin (Dakopatts) for
20 min and rinsed briefly in TBS, followed by incubation
with alkaline phosphatase anti-alkaline phosphatase (APAAP)
complex (diluted 1:40 in TBS, Dako, High Wycombe, Bucks,
UK) for 20 min. In order to increase the staining intensity of
cells incubated with MRK16, the last two steps were repeated
once, the only alteration being that incubation times were
reduced to 10 min. The colour reaction was developed
through use of a substrate based on fast red, which produced
a red reaction in positive cells; cells were counterstained with
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haematoxylin. All of the above steps were repeated on a
negative control slide, substituting an irrelevant isotope-
matched monoclonal antibody (Clonab LC-C, Biotest, UK)
for the primary antibody. As an internal standard, the cell
lines CEM and CEM/VBL100 served as negative and
positive controls. All slides were examined by two experi-
enced observers, and an estimate of P-gp positive cells was
made by counting 100-200 cells in a representative section of
the slide.
Surface marker analysis
Cells were analysed by a direct immunofluorescence assay
using the monoclonal antibody 8G12 (HPCA-2-FITC,
Becton-Dickinson) directed against the CD-34 antigen.
Human AB serum was added to the cell suspension to avoid
unspecific binding. An isotopic control (MsIgGl, Coulter
Immunology) was used in all experiments. Cells were
incubated with the monoclonal at 4°C for 30 min, washed
with PBS and analysed by flow cytometry.
Analysis ofMDR] gene expression bypolymerase chain
reaction (PCR)
RNA was isolated by the guanidine isothiocyanatephenol/ chloroform method (Chomozynsky et al., 1987). cDNA
synthesis and PCR were performed following published pro- cedures (Noonan et al., 1990; Kuwazuru et al., 1990). Briefly, total cellular RNA was first transcribed by murine leukaemia
reverse transcriptase (Bethesda Research Laboratories) ac-
cording to the manufacturer's protocol. cDNA was syn- thesised with 1-3 3fg of total cellular RNA and 100 ng of
random hexadeoxynucleotide primer (Pharmacia) in 20 1l4 reaction mixture containing the enzyme buffer as supplied by Bethesda Research Laboratories, 500ttM each dNTP and 200
units of reverse transcriptase. Incubation was at 37°C for 1 h.
Specific primers for coamplification of mdrl and beta-2-
microglobulin were synthesised on an Applied Biosystems DNA synthesiser and were identical in sequence to those
published by Noonan et al. (1990). PCR was carried out in a
total volume of 100 yl with 1-3jig cDNA using a Gene Amp polymerase chain reaction kit according to the manufac-
turer's instructions (Perkin-Elmer-Cetus, Norwalk, CT) in a
programmable heat block (30-32 cycles). PCR-samples were
then run on an ethidium bromide stained 2% agarose gel.
Results
Indications for bone marrow examination are given in Table
I. Evaluation of bone marrow smears was performed by two
senior haematologists. Twenty-three marrows were considered
to be normal, in two marrows megaloblastic erythropoiesis
was seen and 28 marrows revealed reactive changes such as
left shifted granulopoiesis with or without eosinophilia, lymphocytosis or plasmacytosis. No haemoblastosis or malig-
nant infiltrative disorder was found in any of the specimens examined. As compared to the group of nine bone marrow
donors and eight patients with gammopathy of undetermined
origin, where only two of 17 patients were diagnosed to have
reactive changes in their bone marrow this finding was
significantly more often (24 of 34 patients) seen in patients being examined for other diagnoses such as fever, vasculitis, anaemia, changes in peripheral blood smear, urticaria
pigmentosa, rheumatoid arthritis etc. (Table I).
All in all, 27 of 53 samples (51%) were found to be
positive for C219, that is in 9 of 23 patients (39%) with
normal, one of two patients with megaloblastic and 17 of 28
patients (61%) with reactive bone marrows. The percentage of positive cells ranged from 2%-80% (mean = 24). With a
cutoff point of 10%, 18 patients were considered positive for
P-gp expression, that is five of 23 normal (22%) and 13 of 28
reactive (46%) bone marrows. The difference, while sugges- tive is not statistically significant. Because of recent reports concerning either possible crossreactivity of C219 with other
proteins like muscle myosin (Thiebaut et al., 1989) or con-
tamination of at least some lots of purified C219 with an
anti-A-blood group antibody (Finstad et al., 1991), results
were crosschecked in 24 patients by staining with MRK16
(Table I). An example of immunostaining is given in Figure
1. As reported before (Wishart et al., 1990), staining with
C219 was more intense than with MRK16. The staining
intensity could be increased by repeating two steps of the
APAAP-method for those slides having been incubated with
MRK16. Nevertheless the pattern ofexpression did not differ
significantly and cells stained clearly positive or negative
regardless of the antibody used. Furthermore, a PCR assay
for mdrl gene expression was performed in three C219
negative (patient 18,38,45) and five C219 positive (patient
31,43, 44,46,48) samples to confirm results on the mRNA-
level (Figure 2). In seven of these samples the degree of P-gp
expression had also been confirmed by staining with
MRK16. Results for immunocytochemistry and PCR were in
complete concordance for all samples except 18, the latter
having 2% staining positivity for MRK16, which, in view of
the negative results for C219 and PCR was probably due to
unspecific binding. To examine a possible relationship
between P-gp expression and positivity for the early marker
CD-34, twelve samples were additionally stained with the
monoclonal antibody 8G12 of which seven (patient 1,8,16,
18,19,20,30) had previously stained negative for C219 and
five (patient 15,23,43,48,49) had stained positive (positivity
ranging from 6% to 86%). Flow cytometric analysis did not
reveal more than 1% of CD-34-antigen expressing cells in
any of these samples thus demonstrating that P-gp expression
may be reinduced in CD-34 negative cells. In this context it
would have been of interest to further investigate the possible
lineage specificity of P-gp expression in bone marrow cells.
Unfortunately, since C219 in its FITC-conjugated form is, at
least in our hands, not suitable for double staining
experiments, cell sorting would have been necessary but
could not be performed within the frame of this study
because of the limited amount of material obtained from
each patient.
Although the numbers in each group were small there was
no obvious relationship between diagnosis and P-gp expres-
sion. Negative as well as positive samples were seen in com-
bination with all indications for bone marrow examination.
Likewise age could not be identified as an influential factor.
Discussion
In the present investigation 53 bone marrow samples from
patients with no history ofprior chemotherapy or any malig-
nancy were surveyed for expression of P-gp. Our study
clearly shows that mdrl gene expression, detected by C219
and confirmed by a second mAb MRK16 or for mdrl
mRNA by PCR-amplification of cDNA, can be demon-
strated in a significant proportion of these samples. Other
investigators have either not detected mdrl gene expression
in normal bone marrow or have found the expression to be
very low (Pirker et al., 1989; Noonan et al., 1990; Fojo etal.,
1987). This discrepancy might be due to different methods of
detection. Certain molecular techniques are probably not
sensitive enough to detect mdrl gene expression in a small
population of mdrl positive cells. In contrast, immuno-
cytochemistry allows detection in single or small numbers of
cells. Furthermore, in those studies mentioned above, only a
small number of bone marrow samples of healthy volunteers
was the subject of investigation whereas in our study a
substantial number of samples was taken from patients pres-
enting with some history ofpreceding disease. In this context
it also seems of interest that with a cutoff point of 10%, P-gp
expression was detected in nearly half of the samples
demonstrating reactive changes whereas this was the case in
only 22% of the normal marrows.
In their recently published paper Chaudhary and Roninson
(1991) found P-gp expressed in practically all haematopoetic
progenitor cells of the bone marrow with the highest level ofP-GLYCOPROTEIN EXPRESSION IN NORMAL AND REACTIVE BONE MARROWS 433
Figure 1 Cytospin preparations of bone marrow cells of patient no. 48 stained with an irrelevant isotope matched control
antibody a, C219 b, and MRK16 c. Immunocytochemical labelling by means of the APAAP-method revealed 34% to 43% of P-gp
expressing cells.434 S. HEGEWISCH-BECKER et al.
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Figure 2 Analysis of mdrl mRNA by PCR. Lane numbers refer to patients listed in Table I. The reaction products were analysed
by 2% agarose gel electrophoresis and ethidium bromide staining. DNA fragments generated from single-stranded cDNA
sythesised from RNA by reverse transcriptase, were amplified by 30 to 32 cycles of PCR. Fragments of 167 bp were generated from
cDNA of the multidrug-resistant cell line CEM/VBL 100 and five patients by using the mdrl specific primer set. Fragments of
120 bp were generated in all samples by using the beta2-microglobulin (2 m) specific primer set.
P-gp in those cells displaying characteristics of pluripotent
stem cells, as defined by CD-34 antigen expression (Civin et
al., 1984). There was a positive correlation between the level
of CD-34 expression on the one hand and P-gp expression on
the other hand whereas those cells which became CD-34
negative lost P-gp expression. Thus P-gp expression is present
in haematopoetic precursor cells but disappears during
differentiation. This phenomenon might suggest a possible
function of P-gp in connection with stem cell protection.
Nevertheless, since none of our samples tested for CD-34
expression revealed more than 1% positivity, our results
seem to indicate that under certain circumstances and as part
of the normal physiology P-gp expression can be reinduced
even in CD-34 negative progenitor cells. In this context a
recently published study by Holmes et al. (1990) seems to be
of interest. The authors demonstrated a wide range of mdrl
RNA expression in total nucleated peripheral blood cells of
normal individuals, thus providing evidence that reinduction
of P-gp is not only seen in the bone marrow but also in
peripheral blood cells. One can only speculate about possible
mechanisms leading to this phenomenon. It might represent
an answer to some unknown toxic substances as well as a
regulatory function of differentiation and proliferation of
haematopoetic progenitor cells by means of intracellular
accumulation of certain substances as it was suggested by
Chaudhary and Roninson (1991) for CD-34 positive cells.
Since we found P-gp expression more often in those bone
marrow samples which showed reactive changes one could
also hypothesise on a specific function of the efflux pump
regarding substances that might contribute to these changes.
This seems even more likely since the mdrl gene is expressed
in several normal tissues associated with secretory or barrier
functions and could thus play a significant role in these
processes.
The presence of P-gp in a broad variety of normal tissues
and its possible function as a general detoxification system of
the body makes it even more feasible that cells of the human
bone marrow should use a similar mechanism for
detoxification. To further investigate the role of P-gp and the
mechanism(s) of reinduction in CD-34 antigen negative cells
it would be of interest to determine whether P-gp expression
is lineage specific and whether the pattern of expression in
reactive bone marrows differs from what can be seen in
normal bone marrows.
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